Miyako Capital

Miyako Capital, founded in 2013 and based in Kyoto and Tokyo, Japan, is a venture capital firm that manages the Kyoto University 2nd Venture Fund, among others. The firm focuses on various investment fields, including life sciences and biotechnology, agri-food, environment and energy, as well as IT and electronics. Specific areas of interest encompass drug creation, regenerative medicine, agricultural technologies, alternative energy, and mobile applications. While primarily targeting seed and early-stage investments, Miyako Capital is open to investing in companies across all growth stages, including post-IPO and publicly listed firms associated with Kyoto University. The firm manages several early-stage venture capital funds, including its 2016 and 2020 vintage funds.

Tsunesaburo Sugaya

Managing Director & Partner

33 past transactions

SocialGood, Inc.

Series A in 2022
Social Good Ecosystem is connected with the virtual currency SocialGood and all individuals and companies

VLP Therapeutics

Series A in 2021
VLP Therapeutics, LLC, founded in 2012 by experienced biopharmaceutical professionals, is dedicated to developing innovative medical treatments that enhance traditional vaccine and targeted antibody therapies. Headquartered in Gaithersburg, Maryland, the company focuses on addressing global unmet medical needs through its next-generation inserted alpha VLP (i-αVLP) technology. This approach aims to combat significant public health challenges of the 21st century, enabling healthcare providers to effectively treat cancer, infectious diseases, and autoimmune disorders.

VividQ

Seed Round in 2021
VividQ Limited is a deep tech software company based in Cambridge, United Kingdom, specializing in 3D holography. Founded in February 2017 by a team of Ph.D. graduates, VividQ has developed a comprehensive software platform that enables the generation, compression, and transmission of 3D holographic images and video using standard computing power. Its key products include VividQ Capture, which standardizes 3D data for holographic display; VividQ Squeeze, a solution for compressing point cloud data; and VividQ Core, which facilitates multi-user interactions with holograms. The company also offers VividQ View, an API for integrating spatial light modulators into its holographic systems. VividQ's technology is applicable in a variety of fields, including augmented reality, virtual reality, automotive displays, and consumer electronics. By collaborating with chipmakers and manufacturers, VividQ aims to make holography a commercially viable display solution.

Startbahn

Series B in 2021
Startbahn, Inc. is a Tokyo-based company founded in 2014 that operates a platform focused on enhancing the art experience in the digital age. The company primarily aims to support artists and those involved in the art sector by providing essential technology and services. Startbahn develops Startbahn Cert., a service that issues blockchain certificates for artworks, and promotes Startrail, a blockchain infrastructure that underpins this certification. In addition to its blockchain initiatives, Startbahn is involved in artwork production, art direction, general planning and consulting, as well as information processing for various digital platforms. The company also offers design services for shops and offices, construction management, and print design, contributing to a more connected and innovative art community.

VLP Therapeutics

Series A in 2021
VLP Therapeutics, LLC, founded in 2012 by experienced biopharmaceutical professionals, is dedicated to developing innovative medical treatments that enhance traditional vaccine and targeted antibody therapies. Headquartered in Gaithersburg, Maryland, the company focuses on addressing global unmet medical needs through its next-generation inserted alpha VLP (i-αVLP) technology. This approach aims to combat significant public health challenges of the 21st century, enabling healthcare providers to effectively treat cancer, infectious diseases, and autoimmune disorders.

HACARUS

Series B in 2020
HACARUS Inc. specializes in developing AI solutions for the manufacturing and medical industries, focusing on Explainable Lightweight AI Tools. The company offers several products, including SALUS, a platform for medical and life sciences applications; COLIGO, which provides customized services for IoT and edge computing; and SPECTRO, designed for advanced visual inspections using HACARUS’ proprietary Sparse Modeling technology. This innovative approach allows the AI to analyze data by identifying key features, making it more resource-efficient than traditional deep learning methods. Additionally, HACARUS provides data science consulting and educational services through its AI Academy. Founded in 2014 and based in Kyoto, Japan, HACARUS aims to enhance decision-making processes by delivering reliable AI-driven insights to its clients.

Floadia Corporation

Series C in 2020
Floadia Corporation, established in 2011 and headquartered in Tokyo, Japan, specializes in the development, licensing, and sale of semiconductor intellectual property, with a particular focus on embedded non-volatile memory solutions. The company leverages its engineering team's extensive experience, which includes a background at Renesas, to innovate in embedded FLASH technology. Floadia's expertise encompasses the foundational technology behind widely used FLASH architecture, specifically the "Source Side Injection" method for Split Gate FLASH. In addition to its product offerings, Floadia also provides technology consulting services to support its clients in the semiconductor industry.

Varinos

Seed Round in 2020
Varinos Inc. is a clinical testing company that provides genomic testing and continuous clinical sequencing services. Its services include endometrial microbiome and flow of intrauterine flora testing. The company was founded in 2017 and is based in Tokyo, Japan.

CellAxia

Series B in 2020
CellAxia Inc. engages in development of cell therapy drugs. The company was founded in 2017 and is based in Tokyo, Japan.

Liberaware

Venture Round in 2020
Liberaware Co., Ltd. is a Japanese company that specializes in the development and rental of industrial drones. Founded in 2016 and based in Chiba-shi, the company focuses on managing and analyzing images and flight logs collected by these drones. In addition to its core offerings, Liberaware also develops compact drones designed for maneuvering and pilot training. The company incorporates machine learning and artificial intelligence technologies to enhance its services and products.

BizteX

Series C in 2020
BizteX is a software robotics company that uses cloud Robotic Process Automation to automate routine operations. The company develops SaaS services centered on cloud RPA and expand it globally to contribute to the creation of creativity for many people. The company's service called, BizteX cobit, is a digital robot that performs a one-click substitute for humans by instructing routine work. BizteX was founded in July 2015 and is headquartered in Tokyo, Japan.

Goryo Chemical

Venture Round in 2019
Goryo Chemical, Inc. specializes in the development of fluorescent probes and dyes used in chemical biology and biological applications. The company offers a range of products, including AcidiFluor, CalFluor, GlycoFluor, ProteoFluor, MetalloFluor, ROSFluor, and the IndoCyanine green dye series, alongside bioluminescent probes and custom synthesis services. These products are designed for cellular analysis, assay, and imaging, and can selectively stain acidic organelles such as lysosomes and late endosomes, aiding in the detection of acidic environments. Goryo Chemical provides its products through a network of distributors both in Japan and internationally. Founded in 2010 and headquartered in Sapporo, Japan, with an additional office in Tokyo, the company is recognized as the sole manufacturer of fluorescent dyes in Japan.

Integral Geometry Science

Venture Round in 2019
Integral Geometry Science Inc., founded in 2012 and based in Kobe, Japan, specializes in the design and development of measurement devices and software for image data processing. The company focuses on the inverse analysis theory of electromagnetic and scattered fields, particularly through its innovative microwave mammography system. This technology effectively addresses the challenges associated with scattering microwaves in high-density breasts, producing clear images that assist healthcare professionals in accurately distinguishing between cancerous and normal tissue. By providing a more reliable imaging solution, Integral Geometry Science aims to reduce unnecessary pain and radiation exposure for patients compared to traditional screening methods. Additionally, the company manufactures a nondestructive inspection system specifically for lithium-ion batteries.

Atomis

Series A in 2019
Atomis Inc. is a manufacturer of porous coordination polymers (PCPs), also known as metal-organic frameworks (MOFs), which are designed to spatially confine gas molecules. The company provides a range of evaluation services, including crystal structure analysis, thermal analysis, and gas adsorption and desorption assessments. Atomis is engaged in the research and development of these materials, which are utilized in various applications such as molecular separations, gas transportation, and high-density storage. The company aims to optimize the manufacturing processes of PCPs while developing innovative applications that leverage their unique properties. Founded in 2015 by Masakazu Higuchi, Atomis is headquartered in Kyoto, Japan, and its core technology is based on research by Distinguished Professor Susumu Kitagawa from Kyoto University.

Integral Geometry Science

Venture Round in 2019
Integral Geometry Science Inc., founded in 2012 and based in Kobe, Japan, specializes in the design and development of measurement devices and software for image data processing. The company focuses on the inverse analysis theory of electromagnetic and scattered fields, particularly through its innovative microwave mammography system. This technology effectively addresses the challenges associated with scattering microwaves in high-density breasts, producing clear images that assist healthcare professionals in accurately distinguishing between cancerous and normal tissue. By providing a more reliable imaging solution, Integral Geometry Science aims to reduce unnecessary pain and radiation exposure for patients compared to traditional screening methods. Additionally, the company manufactures a nondestructive inspection system specifically for lithium-ion batteries.

StemRIM

Venture Round in 2018
StemRIM is a biotechnology company based in Ibaraki, Japan, founded in 2006. The company specializes in the development of regeneration-guided medicines aimed at treating challenging diseases such as epidermolysis bullosa, cerebral infarction, and myocardial infarction. StemRIM's innovative approach involves mobilizing the body's own stem cells to target injured or diseased tissues without the need for extraction. Their product portfolio includes PJ1 regeneration induction medicine using HMGB1 peptides, PJ2 and PJ3 regeneration-inducing drugs and proteins, as well as the PJ4 therapeutic autologous cell collection device and PJ5 stem cell gene therapy technology. Through its research and development efforts, StemRIM seeks to advance the field of regenerative medicine and provide effective treatment options for patients with intractable conditions.

HACARUS

Series A in 2018
HACARUS Inc. specializes in developing AI solutions for the manufacturing and medical industries, focusing on Explainable Lightweight AI Tools. The company offers several products, including SALUS, a platform for medical and life sciences applications; COLIGO, which provides customized services for IoT and edge computing; and SPECTRO, designed for advanced visual inspections using HACARUS’ proprietary Sparse Modeling technology. This innovative approach allows the AI to analyze data by identifying key features, making it more resource-efficient than traditional deep learning methods. Additionally, HACARUS provides data science consulting and educational services through its AI Academy. Founded in 2014 and based in Kyoto, Japan, HACARUS aims to enhance decision-making processes by delivering reliable AI-driven insights to its clients.

ARTham Therapeutics

Series A in 2018
ARTham Therapeutics Inc is a biopharmaceutical company based in Naka-Ku, Japan, founded in 2018. The company focuses on developing innovative drugs and therapies aimed at treating debilitating diseases, particularly inflammatory skin conditions, vascular malformations, and endometriosis in the context of immuno-oncology. Its product pipeline includes programs such as art-648, art-ep, art-pde, and art-001, which are designed to address specific medical needs, facilitating faster recovery and improving the quality of life for patients.

Trigence

Series C in 2018
Trigence Semiconductor, Inc. operates as an audio IC design and solution provider. The company offers digital audio products, such as Digital Speaker Module that include speakers, enclosures, connectors, FPCs, audio DSPs, and interfaces to simplify development for PC, tablet, and smartphone required audio functionality; and digital speaker drivers, USBs, and evaluation boards for the consumer and IT markets. It provides products for applications in computer and laptop, headsets, sound-bar, and Bluetooth speaker. The company offers its products through distributors. Trigence Semiconductor, Inc. was founded in 2006 and is based in Tokyo, Japan with offices in Japan, the United States, Hong Kong, and Taiwan.

Megakaryon Corporation

Series C in 2017
Megakaryon Corporation develops platelets and red blood cells from human iPS cell lines. Its portfolio includes blood products that do not depend on blood donations. The company was founded in 2011 and is based in Kyoto, Japan with an additional office in Tokyo, Japan.

StemRIM

Venture Round in 2017
StemRIM is a biotechnology company based in Ibaraki, Japan, founded in 2006. The company specializes in the development of regeneration-guided medicines aimed at treating challenging diseases such as epidermolysis bullosa, cerebral infarction, and myocardial infarction. StemRIM's innovative approach involves mobilizing the body's own stem cells to target injured or diseased tissues without the need for extraction. Their product portfolio includes PJ1 regeneration induction medicine using HMGB1 peptides, PJ2 and PJ3 regeneration-inducing drugs and proteins, as well as the PJ4 therapeutic autologous cell collection device and PJ5 stem cell gene therapy technology. Through its research and development efforts, StemRIM seeks to advance the field of regenerative medicine and provide effective treatment options for patients with intractable conditions.

Institution for a Global Society

Corporate Round in 2017
Institution for a Global Society is a a French graduate school with students from 70 countries around the world

REGiMMUNE

Venture Round in 2017
REGiMMUNE Corporation is a biotechnology company focused on developing immune-regulatory therapeutics aimed at treating various life-threatening diseases and immune disorders. Founded in 2006 and headquartered in Tokyo, Japan, with an office in San Francisco, the company utilizes its proprietary reVax technology to induce regulatory T cells, fostering immune tolerance against specific disease-causing antigens. REGiMMUNE's therapeutic offerings include RGI-2001, currently in a Phase I/II clinical trial for treating Graft versus Host Disease associated with hematopoietic stem cell transplantation, and RGI-1000 for allergy management. The company is also developing RGI-3100 series for type 1 diabetes and other products aimed at preventing inhibitor formation in enzyme replacement therapies and treating inflammatory bowel disease. Their innovative approach seeks to minimize the side effects associated with conventional immunosuppressants while providing effective long-term solutions for conditions such as rheumatoid arthritis and multiple sclerosis.

Drivemode

Series A in 2017
Drivemode, Inc. offers an interaction and feedback technology application for car drivers. Its application suggests drivers to where to go by using their driving pattern, calendar events, and recent texts with address. The company’s application also enables drivers to control their favorite music applications with a tap and swipe; don’t lose navigation whether they make or receive a call; and record their voice instead of typing on phone to get right recommendations at the right time. Drivemode, Inc. was incorporated in 2013 and is based in Redwood City, California. As of September 26, 2019, Drivemode, Inc. operates as a subsidiary of Honda R&D Co.,Ltd.

FLOSFIA

Venture Round in 2017
FLOSFIA INC. is a Tokyo-based company that specializes in the development of corundum structured Gallium Oxide semiconductor power devices. Founded on March 31, 2011, the firm emerged as a spin-off from research conducted at Kyoto University. FLOSFIA focuses on utilizing the unique physical properties of gallium oxide to create low-loss power devices that offer high breakdown voltage and efficiency. The company employs mist chemical vapor deposition (CVD) techniques for film formation, which enhances the performance of its semiconductor products.
KDDD develop an innovative agent effective for various INCURABLE or INTRACTABLE eye diseases, especially CRAO, Retinal Pigmentosa, AMD and Glaucoma.

Integral Geometry Science

Venture Round in 2016
Integral Geometry Science Inc., founded in 2012 and based in Kobe, Japan, specializes in the design and development of measurement devices and software for image data processing. The company focuses on the inverse analysis theory of electromagnetic and scattered fields, particularly through its innovative microwave mammography system. This technology effectively addresses the challenges associated with scattering microwaves in high-density breasts, producing clear images that assist healthcare professionals in accurately distinguishing between cancerous and normal tissue. By providing a more reliable imaging solution, Integral Geometry Science aims to reduce unnecessary pain and radiation exposure for patients compared to traditional screening methods. Additionally, the company manufactures a nondestructive inspection system specifically for lithium-ion batteries.

AFI Japan

Series A in 2016
AFI Japan is a company based in Osaka that specializes in manufacturing cell measuring equipment. The organization focuses on producing products that utilize advanced technology, catering to diverse needs in various sectors. A notable aspect of their offerings includes rapid microbiological testing solutions, which address the growing demand for efficient and accurate testing methods. Through its innovative products and technologies, AFI Japan aims to meet the specific requirements of its clients while contributing to advancements in the field of microbiology.

Farmship

Venture Round in 2015
Farmship, Inc. offers agricultural food distribution services. The company was founded in 2014 and is based in Tokyo, Japan.

Megakaryon Corporation

Series B in 2015
Megakaryon Corporation develops platelets and red blood cells from human iPS cell lines. Its portfolio includes blood products that do not depend on blood donations. The company was founded in 2011 and is based in Kyoto, Japan with an additional office in Tokyo, Japan.

Helpfeel

Series A in 2014
Nota, Inc. is a technology company that develops and provides a collaborative web platform designed for creating, sharing, and collaborating on presentations and various forms of online content. It offers Nota for Education, a tool aimed at students and educators to facilitate the creation and sharing of documents such as presentations, notebooks, and reports. Nota is also known for Gyazo, a popular cloud-based screen capture and sharing application that allows users to easily share screenshots via custom URLs. With a user base exceeding 8 million, Gyazo has experienced significant growth through viral acquisition strategies. Founded in 2007, Nota operates from Menlo Park, California, and has additional offices in Kyoto and Tokyo, Japan, reflecting its ambition to blend global outreach with its Japanese roots.

iHeart Japan

Series A in 2014
iHeart Japan Corporation focuses on developing innovative regenerative medicinal products aimed at treating severe heart failure. The company utilizes induced pluripotent stem cell (iPSC) technologies, which were pioneered by researchers at Kyoto University, including Prof. Jun K Yamashita from the Center for iPS Cell Research and Application. The goal of iHeart Japan is to create next-generation therapies that can serve as alternatives to heart transplantation, potentially transforming the approach to cardiac care.

MONEY DESIGN

Seed Round in 2014
MONEY DESIGN Co., Ltd. offers asset management and investment advice services. The company was founded in 2013 and is based in Tokyo, Japan.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.